Patents by Inventor Anne JACQUET

Anne JACQUET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSOCIATION BETWEEN INTEGRATION OF HIGH-RISK HPV GENOMES DETECTED BY MOLECULAR COMBING AND THE SEVERITY AND/OR CLINICAL OUTCOME OF CERVICAL LESIONS
    Publication number: 20220267868
    Abstract: The invention involves methods for identification of biomarkers of the severity of an HPV infection.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 25, 2022
    Applicant: GENOMIC VISION
    Inventors: Fanny LEMEE, Stephanie BOUCHILLOUX, Sebastien BARRADEAU, Anne JACQUET, Aaron BENSIMON
  • ASSOCIATION BETWEEN INTEGRATION OF HIGH-RISK HPV GENOMES DETECTED BY MOLECULAR COMBING AND THE SEVERITY AND/OR CLINICAL OUTCOME OF CERVICAL LESIONS
    Publication number: 20200190607
    Abstract: The invention involves methods for identification of biomarkers of the severity of an HPV infection.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: GENOMIC VISION
    Inventors: Fanny LEMEE, Stephanie BOUCHILLOUX, Sebastien BARRADEAU, Anne JACQUET, Aaron BENSIMON
  • ASSOCIATION BETWEEN INTEGRATION OF HIGH-RISK HPV GENOMES DETECTED BY MOLECULAR COMBING AND THE SEVERITY AND/OR CLINICAL OUTCOME OF CERVICAL LESIONS
    Publication number: 20190112673
    Abstract: The invention involves methods for identification of biomarkers of the severity of an HPV infection.
    Type: Application
    Filed: May 10, 2018
    Publication date: April 18, 2019
    Applicant: GENOMIC VISION
    Inventors: Fanny LEMEE, Stephanie BOUCHILLOUX, Sebastien BARRADEAU, Anne JACQUET, Aaron BENSIMON
  • ASSOCIATION BETWEEN 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR KINASE INHIBITOR
    Publication number: 20170027952
    Abstract: Association between 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione of formula (I): or a Z or E isomer thereof and/or an addition salt thereof with a pharmaceutically acceptable acid or base, and a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Medicinal products containing the same which are useful in treating non-small cell lung cancer.
    Type: Application
    Filed: July 26, 2016
    Publication date: February 2, 2017
    Inventors: Michael BURBRIDGE, Valérie CATTAN, Anne JACQUET-BESCOND
  • ASSOCIATION BETWEEN N-HYDROXY-4-BENZAMIDE AND FOLFOX
    Publication number: 20150038513
    Abstract: Association between N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-yl-carbonylamino]ethoxy}benzamide of formula (I): an addition salt thereof with a pharmaceutically acceptable acid or base, and FOLFOX. Medicaments.
    Type: Application
    Filed: July 3, 2012
    Publication date: February 5, 2015
    Inventors: Stéphane Depil, Anne Jacquet-Bescond, Ioana Kloos, Anne-Laure Sarry, Sriram Balasubramanian, Joseph Buggy
  • ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE
    Publication number: 20150024040
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stéphane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
    Patent number: 8883199
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • ADMINISTRATION REGIME FOR N-HYDROXY-4-BENZAMIDE
    Publication number: 20130064880
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 14, 2013
    Applicants: LES LABORATOIRES SERVIER
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stéphane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian